Actelion aims to defend market leadership in pulmonary arterial hypertension.
By Armando Uribe, Analytics Analyst
22 June 2016
Datamonitor Healthcare forecasts that Actelion’s prescription pharmaceutical sales will grow at a compound annual growth rate of 8.0%, reaching sales of $4,581m by 2025. Actelion is forecast to see significant growth despite experiencing the genericization of Tracleer (bosentan) for pulmonary arterial hypertension (PAH), the company’s most profitable drug in 2015. Actelion’s main strategic goal in recent years has been to develop or acquire products that will solidify its position as one of the leading companies in the PAH market. This has led to the discovery and development of the next-generation ERA, Opsumit (macitentan), and novel oral prostacyclin in Uptravi (selexipag).
Datamonitor Healthcare forecasts that Opsumit will become the highest revenue generating product for Actelion by 2025, reaching global sales of $1.9bn. This is attributed to Opsumit’s strong clinical profile reflected in its label and the company’s competitive pricing strategy. Alternative PAH therapies, such as Adempas (riociguat; Bayer), Letairis (ambrisentan; Gilead), and Revatio (sildenafil; Pfizer), all have labels that focus on improving disease symptoms, such as improving exercise capacity and ability or delaying clinical worsening. Conversely, Opsumit’s label reflects approval to delay disease progression – defined as death, initiation of intravenous or subcutaneous prostanoids, or clinical worsening of PAH. Additionally, Actelion has priced Ospumit at parity to Tracleer, facilitating patient transfer between products and reducing the risk of reimbursement or other cost concerns.
Actelion’s novel oral prostacyclin Uptravi (selexipag) is also forecast to expand the company’s share in PAH throughout the forecast period. Uptravi has positioned itself to be the first choice prostacyclin in the United States, outperforming first to market oral prostacyclin receptor Orenitram (treprostinil; United Therapeutics). In January 2016, Uptravi was launched in the US and generated $35,230m by the end of Q1 2016. Datamonitor Healthcare forecasts that Uptravi will generate $117m in 2016 and will reach over $1.5bn in worldwide sales by 2025.
Datamonitor Healthcare’s company analysis on Actelion explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>